Reduced Fracture Risk and Increased Bone Density in women with postmenopausal osteoporosis
TYMLOS Reduced Fracture Risk and Increased Bone Density
In a clinical trial, women taking TYMLOS were compared with women taking a placebo (an injection that did not contain any medication) for 18 months. The study showed that at 18 months, women taking TYMLOS had:
Lower risk of having a spinal fracture
Women taking TYMLOS had an 86% lower chance of getting a spinal fracture than those on placebo.
(0.6% of women taking TYMLOS had a fracture
vs 4.2% taking placebo)
Lower risk of having fractures in other bones*
Compared with placebo, women taking TYMLOS had a 43% lower risk of non-spinal fractures.
(2.7% of women taking TYMLOS had a fracture compared to 4.7% of women taking placebo)
*Fractures of the breast bone, kneecap, toes, fingers, skull and face, and those associated with high trauma were not included.
Increased bone density
Women taking TYMLOS had significant increases in bone mineral density (BMD) in the spine and hip, compared with women taking placebo.
At the start of the trial, women had the following average T-scores:
- Lumbar spine (lower back): -2.9
- Femoral neck (the area just below the ball joint of the hip): -2.1
- Total hip: -1.9
Women had the following average T-scores at 18 months:
- Lumbar spine (lower back): -2.1
- Femoral neck (the area just below the ball joint of the hip): -1.96
- Total hip: -1.63